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Background: SPECT imaging with 123I-MIBG was reported to have prognostic value in heart failure (HF), but the image quality was poor. LMI1195 
is a newly developed imaging agent labeled with 18F to take technical advantages of PET over SPECT. Like 123I-MIBG, LMI1195 was designed as a 
substrate of the norepinephrine transporter (NET). 
Methods: LMI1195 was assessed in cell membrane and human neuroblastoma cells (SH-SY5Y) with high expression of NET, and in various animal 
species including non-human primates (NHP). 
Results: In the cell membrane, the Ki value of LMI1195 was measured as 5.16 ± 0.93 μM. In SH-SY5H cells, LMI1195 uptake was inhibited by 
desipramine, a selective NET inhibitor, and the uptake kinetics was determined with Km and Vmax values of 6.78 ± 1.94 μM and 5.18 ± 1.23 pmol/
min/million cells, which were similar to that of MIBG (2.12 ± 0.26 μM and 4.76 ± 0.78 pmol/min/million cells). In-vivo tissue sampling, LMI1195 
heart uptake at 15- and 60-min post i.v. injection was 2.36 ± 0.16 and 2.17 ± 0.12 % injected dose per g tissue (%ID/g) in rats and 0.25 ± 0.03 
and 0.28 ± 0.03 %ID/g in rabbits. In rabbits, desipramine (1 mg/kg) inhibited heart uptake of LMI1195 by 68% and 123I-MIBG by 55% at 1-hr 
post dose. Sympathetic denervation with 6-hydroxydopamine (6-OHDA), a neurotoxin, resulted in a marked decrease in LMI1195 heart uptake by 
79%. Cardiac imaging with LMI1195 revealed clear myocardium with low background interference in rats, rabbits and NHPs. Consistent with tissue 
sampling, imaging in rabbits pretreated with desipramine showed reduced heart radioactivity levels in a dose dependent manner. Similarly, rabbits 
pretreated with 6-OHDA resulted in low cardiac image intensity with LMI1195 but normal perfusion images with BMS747158. In NHPs pretreated 
with desipramine (0.5 mg/kg), imaging with LMI1195 showed a decreased myocardial radioactivity by 68%. In HF model of Dahl-salt sensitive rats 
fed a high salt diet, LMI1195 heart uptake decreased progressively following the progression of HF.
Conclusions: LMI1195 is a novel cardiac PET imaging agent transported into the heart via NET. With improved cardiac image quality, it should 
provide better assessment of cardiac neuronal function for HF stratification.
